These findings shed light on our understanding of the role that the Mn exporter SLC30A10 plays in the pathophysiology of HMDPC, and they provide experimental evidence for targeting ATP2C1 in managing HMDPC and related disorders. The gene discussed is ATP2C1; the disease is cirrhosis - dystonia - polycythemia - hypermanganesemia syndrome.